Pasithea Therapeutics
KTTA
9 hedge funds and large institutions have $1.03M invested in Pasithea Therapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
56% more capital invested
Capital invested by funds: $662K → $1.03M (+$370K)
0.01% more ownership
Funds ownership: 0.14% → 0.15% (+0.01%)
10% less funds holding
Funds holding: 10 → 9 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$95.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$92.6K |
| 3 |
OWP
Old Well Partners
Charlotte,
North Carolina
|
+$38.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.99K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$15K |
| 2 |
SG
StoneX Group
New York
|
-$12.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KPF
1
K2 Principal Fund
Toronto,
Ontario, Canada
| $620K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $201K | +$95.9K | +4,085 | +105% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $124K | +$92.6K | +3,944 | +400% |
|
|
OWP
4
Old Well Partners
Charlotte,
North Carolina
| $42K | +$38.7K | +1,650 | New |
|
5
State Street
Boston,
Massachusetts
| $30K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $7K | -$8.62K | -367 | -57% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $7K | +$3.99K | +170 | +150% |
|
8
JP Morgan Chase
New York
| $1K | – | – | – |
|
|
VF
9
Virtu Financial
New York
| – | -$15K | -729 | Closed |
|
|
SG
10
StoneX Group
New York
| – | -$12.1K | -600 | Closed |
|
|
11
Wells Fargo
San Francisco,
California
| – | +$23 | +1 | +20% |
|
KTTA Hedge Fund Activity: Q3 2022 in Review
9 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2022, worth a combined $1.03M — up 56% from $662K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of KTTA and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $95.9K. The largest seller was Virtu Financial, exiting entirely with an estimated $15K sold.
- 9 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2022, down from 10 in Q2 2022.
- Funds reported $1.03M of Pasithea Therapeutics stock for Q3 2022, up 56% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics positions in Q3 2022 and 2 closed out, a net change of -1 holder.
- The largest Pasithea Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $95.9K added.
- The largest Pasithea Therapeutics seller in Q3 2022 was Virtu Financial, an estimated $15K sold.
Based on aggregated 13F filings for Q3 2022.